Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human G-CSF Protein,HEK293 Expressed, 50µg  

Recombinant Human G-CSF Protein,HEK293 Expressed, 50µg

Recombinant Human G-CSF / GCSFb Protein, HEK293 Expressed (rhG-CSF) Ala 31 - Pro 204, was produced in human 293 cells (HEK293), ActiveMaxCytokine

Synonyms: CSF3, G-CSF, MGC45931, C17orf33, CSF3OS, Granulocyte colony-stimulating factor, Granulocyte/macrophage colony-stimulating factors, Pluripoietin, G-CSF protein

More details

GCF-H5214-050

Availability: within 7 days

576,00 €

Background: Granulocyte colony-stimulating factor (G-CSF or GCSF), also known as colony-stimulating factor 3, CSF3, C17orf33, CSF3OS, GCSF, MGC45931. It is a glycoprotein, growth factor and cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood. G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils. G-CSF regulates them using Janus kinase (JAK)/signal transducer and activator of transcription (STAT) and Ras /mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signal transduction pathway. G-CSF is produced by endothelium, macrophages, and a number of other immune cells. The natural human glycoprotein exists in two forms, a 174- and 180-amino-acid-long protein of molecular weight 19,600 grams per mole. G-CSF can effect on the hematopoietic system and neuronal cells as a neurotrophic factor. The action of G-CSF in the central nervous system is to induce neurogenesis, to increase the neuroplasticity and to counteract apoptosis.[1, 2] G-CSF stimulates the production of white blood cells (WBC). In oncology and hematology, a recombinant form of G-CSF is used with certain cancer patients to accelerate recovery from neutropenia after chemotherapy, allowing higher-intensity treatment regimens. Another form of recombinant human G-CSF called lenograstim is synthesised in Chinese Hamster Ovary cells (CHO cells). The recombinant human G-CSF synthesised in an E. coli expression system is called filgrastim.

Source
Recombinant Human G-CSF / GCSFb Protein, HEK293 Expressed (rhG-CSF) Ala 31 - Pro 204, (Accession# NP_757373) was produced in human 293 cells (HEK293)

Molecular Characterization
rhG-CSF, a 174 amino acids protein and has a calculated MW of 18.7 kDa. The predicted N-terminus is Thr2. DTT-reduced protein migrates as 18-21 kDa protein due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhG-CSF by the LAL method.

Purity
>95% purity as determined by SDS-PAGE of reduced rhG-CSF.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization. 

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
Immobilized Human FGF basic, Tag Free (Cat. No. BFF-H4117) at 0.5 μg/mL (100 μL/well) can bind Human Glypican 3 (S359F), low endotoxin (Cat. No. GP3-H5223) with a linear range of 3-128 ng/mL (QC tested). Immobilized Human Glypican 3 (S359F), low endotoxin (Cat. No. GP3-H5223) at 0.5 μg/mL (100 μL/well) can bind Anti-Human GPC3 Mab with a linear range of 0.4-3 ng/mL (Routinely tested).


References

(1) Schneider A,, et al., 2005, J. Clin. Invest. 115 (8): 2083–98.
(2) Pitzer C, et al., 2008, Brain 131 (Pt 12): 3335–47.